FDA OKs Bimzelx for psoriatic arthritis, ankylosing spondylitis, non-radiographic axSpA

The FDA has expanded the indication of Bimzelx to include psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis with objective signs of inflammation, according to a press release.
The approvals apply to adults with active disease. The drug had previously been approved for moderate-to-severe plaque psoriasis in October 2023. According to the release from the manufacturer, Bimzelx (bimekizumab-bkzx, UCB) is now the first and only interleukin -17A and IL-17F inhibitor approved by the FDA to treat four chronic immune-mediated inflammatory diseases.
“The

The FDA has expanded the indication of Bimzelx to include psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis with objective signs of inflammation, according to a press release.
The approvals apply to adults with active disease. The drug had previously been approved for moderate-to-severe plaque psoriasis in October 2023. According to the release from the manufacturer, Bimzelx (bimekizumab-bkzx, UCB) is now the first and only interleukin -17A and IL-17F inhibitor approved by the FDA to treat four chronic immune-mediated inflammatory diseases.
“The